Differential long noncoding RNA expressions in peripheral blood mononuclear cells for detection of acute ischemic stroke.
Qi-Wen Deng, Shuo Li, Huan Wang...
https://pubmed.ncbi.nlm.nih.gov/29997237Actively Recruiting
Age: 18Years - 90Years
All Genders
ID04230785
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2026-04-09
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
Nanjing First Hospital, Nanjing Medical University
Lead Sponsor
Z
Zhongda Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on acute ischemic stroke patients undergoing endovascular treatment. It aims to study the patterns of certain non-coding RNAs—circular RNA, long non-coding RNA, and micro-RNA—before and after treatment. These RNA types are being explored as potential biomarkers and regulators for stroke progression and prognosis, as well as their impact on the immune system following stroke. The study observes two groups of patients: those before and those after endovascular treatment. It uses advanced genetic techniques like next-generation sequencing and quantitative real-time polymerase chain reaction to analyze the RNA expression. Researchers will identify specific RNA patterns and develop a predictive model to relate these findings to immune status and stroke outcomes. Participants will have their RNA levels measured and monitored for 90 days to assess changes over time. The study also examines the relationship between these RNAs and inflammatory factors, stroke-associated infections, and overall prognosis. This observational study does not involve experimental treatments but collects detailed biological data to better understand stroke recovery and treatment effects.
CONDITIONS
Brief Title
Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
Who Can Participate
Age: 18Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Confirmed acute ischemic stroke by diffusion-weighted MRI and brain CT scan
- Within 24 hours of symptom onset and receiving endovascular therapy
- Good performance status
- Signed an approved informed consent
You will not qualify if you...
- History of hemorrhagic infarction
- Chronic kidney or liver diseases
- Peripheral arterial occlusive disease
- Active malignant disease
- Inflammatory or infectious diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Within 24 hours of symptom onset
Participants undergo assessments including diffusion-weighted MRI and brain CT scan to confirm acute ischemic stroke.
1 visit (in-person)
Monitoring
Duration - Up to 90 days
Participants are observed to evaluate the expression patterns of non-coding RNA before and after endovascular treatment.
Multiple visits during the 90-day follow-up period
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China, 210006
Actively Recruiting
Loading map...
Research Team
J
Junshan Zhou, M.D
Q
Qiwen Deng, M.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here